UA120353C2 - Модулятори натрієвого каналу для лікування болю і діабету - Google Patents
Модулятори натрієвого каналу для лікування болю і діабету Download PDFInfo
- Publication number
- UA120353C2 UA120353C2 UAA201603676A UAA201603676A UA120353C2 UA 120353 C2 UA120353 C2 UA 120353C2 UA A201603676 A UAA201603676 A UA A201603676A UA A201603676 A UAA201603676 A UA A201603676A UA 120353 C2 UA120353 C2 UA 120353C2
- Authority
- UA
- Ukraine
- Prior art keywords
- chloro
- propyl
- fluoro
- thiazol
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876046P | 2013-09-10 | 2013-09-10 | |
| PCT/US2014/054764 WO2015038533A2 (en) | 2013-09-10 | 2014-09-09 | Sodium channel modulators for the treatment of pain and diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA120353C2 true UA120353C2 (uk) | 2019-11-25 |
Family
ID=52666496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201603676A UA120353C2 (uk) | 2013-09-10 | 2014-09-09 | Модулятори натрієвого каналу для лікування болю і діабету |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20160221974A1 (enExample) |
| EP (1) | EP3043787B1 (enExample) |
| JP (1) | JP6445565B2 (enExample) |
| KR (1) | KR20160054570A (enExample) |
| CN (1) | CN105611923B (enExample) |
| AU (1) | AU2014318979B2 (enExample) |
| BR (1) | BR112016005271A2 (enExample) |
| CA (1) | CA2922851C (enExample) |
| ES (1) | ES2687598T3 (enExample) |
| IL (1) | IL244506B (enExample) |
| MX (1) | MX2016002881A (enExample) |
| MY (1) | MY181928A (enExample) |
| PH (1) | PH12016500296A1 (enExample) |
| RU (1) | RU2016113156A (enExample) |
| SG (2) | SG10201805552PA (enExample) |
| UA (1) | UA120353C2 (enExample) |
| WO (1) | WO2015038533A2 (enExample) |
| ZA (1) | ZA201702410B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015022096A8 (pt) * | 2013-03-15 | 2019-11-26 | Chromocell Corp | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos |
| CN105611923B (zh) | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
| WO2016040315A1 (en) * | 2014-09-09 | 2016-03-17 | Chromocell Corporation | Selective nav1.7 inhibitors for the treatment of diabetes |
| TW201726637A (zh) | 2015-12-18 | 2017-08-01 | 默沙東藥廠 | 對電位閘控鈉通道具選擇活性之羥基烷基胺－及羥基環烷基胺－取代之二胺－芳基磺胺化合物 |
| KR102366077B1 (ko) | 2016-05-20 | 2022-02-21 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| CN105924670A (zh) * | 2016-06-02 | 2016-09-07 | 扬州兰都塑料科技有限公司 | 一种电力电缆用耐磨剂 |
| CN105924843A (zh) * | 2016-06-02 | 2016-09-07 | 扬州兰都塑料科技有限公司 | 一种耐刮擦的电力电缆 |
| CN106084535A (zh) * | 2016-06-02 | 2016-11-09 | 扬州兰都塑料科技有限公司 | 一种耐刮擦的电力电缆的制备方法 |
| KR20190086772A (ko) | 2016-12-09 | 2019-07-23 | 제논 파마슈티칼스 인크. | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 |
| CN106892845B (zh) * | 2017-02-28 | 2018-10-30 | 四川同晟生物医药有限公司 | 一种2,4-二氨基丁酸衍生物及其制备方法 |
| WO2019200369A1 (en) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage |
| WO2019217822A1 (en) * | 2018-05-11 | 2019-11-14 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions |
| BR112020024729A2 (pt) | 2018-06-13 | 2021-03-23 | Xenon Pharmaceuticals, Inc. | compostos de benzenossulfonamida e seu uso como agentes terapêuticos |
| CA3104913A1 (en) | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| IL279810B2 (en) | 2018-08-31 | 2025-03-01 | Xenon Pharmaceuticals Inc | Heteroaryl-modified sulfonamide compounds and their use as medicinal agents |
| CN113527281B (zh) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | 杂环化合物及其制备方法和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| ATE404568T1 (de) * | 2001-03-14 | 2008-08-15 | Gruenenthal Gmbh | Substituierte thiazolopyrimidine als analgetika |
| US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| AU2003243921B2 (en) | 2002-06-27 | 2009-05-07 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| WO2005054202A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| AU2005245386B2 (en) | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| AP2007003887A0 (en) * | 2004-07-23 | 2007-02-28 | Pfizer | Pyridine derivatives |
| CA2584413A1 (en) | 2004-10-29 | 2006-05-04 | Astrazeneca Ab | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases |
| DK1966130T3 (da) * | 2005-12-23 | 2014-02-10 | Zealand Pharma As | Modificerede lysin-mimetiske forbindelser |
| JP2010518026A (ja) * | 2007-02-05 | 2010-05-27 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物 |
| CA2694748A1 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
| HUE025013T2 (hu) * | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| CN105254557A (zh) | 2009-05-29 | 2016-01-20 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| JP2013525368A (ja) | 2010-04-23 | 2013-06-20 | キネタ・インコーポレイテツド | 抗ウイルス性化合物 |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| JP5860045B2 (ja) | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| CA2804593C (en) * | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| WO2012007883A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
| JP2014507136A (ja) | 2011-01-18 | 2014-03-27 | アムジエン・インコーポレーテツド | ＮａＶ１．７ノックアウトマウスとそれらの使用 |
| TWI622583B (zh) * | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| AU2012296529A1 (en) | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| AU2012312266A1 (en) | 2011-09-21 | 2013-05-02 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| EP2919770A4 (en) | 2012-11-14 | 2017-03-08 | The Board of Regents of The University of Texas System | Inhibition of hif-2 heterodimerization with hif1 (arnt) |
| BR112015022096A8 (pt) * | 2013-03-15 | 2019-11-26 | Chromocell Corp | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos |
| SG11201601616SA (en) | 2013-09-09 | 2016-04-28 | Peloton Therapeutics Inc | Aryl ethers and uses thereof |
| CN105611923B (zh) | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
| WO2016040315A1 (en) | 2014-09-09 | 2016-03-17 | Chromocell Corporation | Selective nav1.7 inhibitors for the treatment of diabetes |
-
2014
- 2014-09-09 CN CN201480049690.8A patent/CN105611923B/zh not_active Expired - Fee Related
- 2014-09-09 UA UAA201603676A patent/UA120353C2/uk unknown
- 2014-09-09 KR KR1020167009294A patent/KR20160054570A/ko not_active Ceased
- 2014-09-09 SG SG10201805552PA patent/SG10201805552PA/en unknown
- 2014-09-09 RU RU2016113156A patent/RU2016113156A/ru not_active Application Discontinuation
- 2014-09-09 SG SG11201601367QA patent/SG11201601367QA/en unknown
- 2014-09-09 EP EP14843353.5A patent/EP3043787B1/en active Active
- 2014-09-09 MY MYPI2016700824A patent/MY181928A/en unknown
- 2014-09-09 US US15/021,153 patent/US20160221974A1/en not_active Abandoned
- 2014-09-09 CA CA2922851A patent/CA2922851C/en active Active
- 2014-09-09 JP JP2016540921A patent/JP6445565B2/ja active Active
- 2014-09-09 BR BR112016005271-4A patent/BR112016005271A2/pt not_active IP Right Cessation
- 2014-09-09 ES ES14843353.5T patent/ES2687598T3/es active Active
- 2014-09-09 WO PCT/US2014/054764 patent/WO2015038533A2/en not_active Ceased
- 2014-09-09 AU AU2014318979A patent/AU2014318979B2/en not_active Ceased
- 2014-09-09 MX MX2016002881A patent/MX2016002881A/es active IP Right Grant
-
2016
- 2016-01-13 US US14/994,846 patent/US9458118B2/en active Active
- 2016-02-12 PH PH12016500296A patent/PH12016500296A1/en unknown
- 2016-03-09 IL IL244506A patent/IL244506B/en active IP Right Grant
-
2017
- 2017-04-05 ZA ZA2017/02410A patent/ZA201702410B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL244506A0 (en) | 2016-04-21 |
| ES2687598T3 (es) | 2018-10-26 |
| ZA201702410B (en) | 2019-06-26 |
| EP3043787B1 (en) | 2018-09-05 |
| US20160130239A1 (en) | 2016-05-12 |
| RU2016113156A3 (enExample) | 2018-07-02 |
| SG11201601367QA (en) | 2016-03-30 |
| BR112016005271A2 (pt) | 2020-05-12 |
| PH12016500296A1 (en) | 2016-05-16 |
| WO2015038533A2 (en) | 2015-03-19 |
| AU2014318979B2 (en) | 2019-03-28 |
| CN105611923A (zh) | 2016-05-25 |
| AU2014318979A1 (en) | 2016-03-03 |
| CA2922851A1 (en) | 2015-03-19 |
| US20160221974A1 (en) | 2016-08-04 |
| KR20160054570A (ko) | 2016-05-16 |
| CA2922851C (en) | 2023-03-14 |
| RU2016113156A (ru) | 2017-10-16 |
| EP3043787A2 (en) | 2016-07-20 |
| MX2016002881A (es) | 2016-04-21 |
| EP3043787A4 (en) | 2017-02-01 |
| JP6445565B2 (ja) | 2018-12-26 |
| IL244506B (en) | 2020-02-27 |
| US9458118B2 (en) | 2016-10-04 |
| CN105611923B (zh) | 2019-08-23 |
| JP2016532716A (ja) | 2016-10-20 |
| SG10201805552PA (en) | 2018-08-30 |
| WO2015038533A3 (en) | 2015-10-29 |
| MY181928A (en) | 2021-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2669367C2 (ru) | Модуляторы натриевого канала для лечения боли | |
| EP2358371B1 (en) | P2x3, receptor antagonists for treatment of pain | |
| US10662200B2 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| CN105611923B (zh) | 用于治疗疼痛和糖尿病的钠通道调节剂 | |
| EP3720858B1 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| KR20210118816A (ko) | 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법 | |
| EA019252B1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ | |
| WO2014151959A1 (en) | N-alkyl-2-phenoxyethanamines, their preparation and use | |
| JP2023036694A (ja) | 皮膚におけるｃ－Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法 | |
| KR20200139702A (ko) | 칼페인 조정자 및 그 치료학적 용도 | |
| JP2021523934A (ja) | ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物 | |
| CA3154504A1 (en) | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino )isoindoline-1,3-dione | |
| JP2017527573A (ja) | 糖尿病の治療用の選択的ＮａＶ１．７阻害剤 | |
| JP6808154B2 (ja) | アダマンタン誘導体およびその使用 | |
| BRPI0618284A2 (pt) | derivado de pirazolo-[4,3-d]-pirimidin-5-il usado como inibidores de pde5 | |
| EP4620957A1 (en) | Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof | |
| KR20260062959A (ko) | 암 치료에서 사용하기 위한 bcr:abl-1 저해제와 제2 타이로신 키나제 저해제를 포함하는 조합물 | |
| HK40086209B (zh) | 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 | |
| WO2025092884A1 (zh) | 治疗白血病的方法 | |
| HK40086209A (zh) | 用於治疗神经退行性疾病和线粒体疾病的组合物及其使用方法 | |
| CA3255975A1 (en) | Flavonoid compounds, as well as methods and materials for using flavonoid compounds to treat fibrotic conditions | |
| HK1224572A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| WO2014077532A1 (ko) | 신규한 피페라진 유도체, 이의 약학적으로 허용가능한 염 또는 이의 광학이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사질환 예방 또는 치료용 약학적 조성물 | |
| HK40039344B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40039344A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto |